Our algorithms reduce the possible combination and sequence space to the designs that can deliver durable control — now advancing through partner and internal programmes.
Paired with our combination optimisation engine, the model points to the potential to move diseases like PDAC from a current median overall survival of roughly 8–11 months to 84+ months — by finding the combinations and sequences that come close to fully eradicating cancerous cells, largely from assets already in clinical use. We're building those combinations in-house and with partners.
Illustrative, model-based projection from current outputs — not a clinical or regulatory claim. Validation ongoing; figures to be confirmed and referenced as programmes mature.
We go deliberately narrow: novel synergies where the agents have never been observed together and conventional models have nothing reliable to interpolate from. By reasoning from mechanism and an evolving disease state, we can evaluate combinations at the cutting edge of immunotherapy before a comparable clinical dataset exists.
Today that means repurposing post-Phase 2 assets into better combinations, designing novel assets and combinations, and partnering across cancers, immune diseases and neurological diseases.
| Partner | Indication | Approach | Stage |
|---|---|---|---|
| Biotech 01 | Osteosarcoma | Novel-target small molecule | Design |
| Biotech 01 | Esophageal | Novel-target small molecule | Design |
| Biotech 02 | Prostate | Phase 2+ combination via viral delivery | Design |
| Biotech 03 | Pancreatic | Matrix-degradation biologic + existing drug | Design |
| Biotech 03 | Prostate | Matrix-degradation biologic + existing drug | Design |
| Biotech 04 | Pancreatic | Resistance-modifying small-molecule combo | Design |
| Pharma 01–04 | scope tbd | Top-10 · oncology BD discussion | Early discussion |
| Internal | TBD within 6 months | Common pan-cancer strategies from a programme-level hallmark map | Scoping |
Partners shown anonymised. Programme details are indicative and evolve as work progresses.
We de-risk partners' combinations with the world model, and advance our own programmes: starting in oncology, then the immune and neural systems where single-target thinking has failed for decades.
Every engagement starts with a single question and can grow into a scoped programme, a co-development partnership, or standing coverage.